Free Trial

TD Private Client Wealth LLC Invests $291,000 in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Jazz Pharmaceuticals logo with Medical background

TD Private Client Wealth LLC acquired a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,346 shares of the specialty pharmaceutical company's stock, valued at approximately $291,000.

Several other hedge funds have also recently modified their holdings of the stock. Fuller & Thaler Asset Management Inc. increased its holdings in Jazz Pharmaceuticals by 117.4% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock worth $115,681,000 after buying an additional 507,234 shares during the period. Darwin Global Management Ltd. acquired a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $59,668,000. Perpetual Ltd increased its holdings in Jazz Pharmaceuticals by 60.2% in the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock worth $118,212,000 after buying an additional 357,784 shares during the period. Dimensional Fund Advisors LP increased its holdings in Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after buying an additional 320,724 shares during the period. Finally, Ameriprise Financial Inc. increased its holdings in Jazz Pharmaceuticals by 20.9% in the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after buying an additional 315,608 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total value of $116,350.00. Following the transaction, the chief executive officer owned 439,307 shares in the company, valued at approximately $51,113,369.45. This trade represents a 0.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Seamus Mulligan purchased 100,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 9th. The shares were bought at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the acquisition, the director owned 100,000 shares in the company, valued at approximately $9,826,000. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 2,500 shares of company stock worth $277,930 in the last 90 days. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ traded up $1.17 during midday trading on Monday, reaching $111.44. 492,158 shares of the company's stock traded hands, compared to its average volume of 830,135. The company has a fifty day simple moving average of $108.32 and a two-hundred day simple moving average of $118.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38. The company has a market cap of $6.74 billion, a P/E ratio of 14.86, a PEG ratio of 4.76 and a beta of 0.32. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The company's revenue for the quarter was down .5% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.68 EPS. Equities analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Robert W. Baird dropped their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Piper Sandler reaffirmed an "overweight" rating and set a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Royal Bank Of Canada dropped their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Morgan Stanley dropped their price objective on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Finally, Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $184.00.

Get Our Latest Research Report on JAZZ

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Read More

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Should You Invest $1,000 in Jazz Pharmaceuticals Right Now?

Before you consider Jazz Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.

While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines